|
|
Studies
|
|
 |
|
New Programs(25 Records found)
CTO#: 101705
Lip, Oral Cavity and Pharynx
Status: Active/Enrolling
Sponsor: RTOG (1016)
PHASE III TRIAL OF RADIOTHERAPY PLUS CETUXIMAB VERSUS CHEMORADIOTHERAPY IN HPV-ASSOCIATED OROPHARYNX CANCER
Lay Description:
HIPAA
Informed Consent
Protocol
...details...
CTO#: 101640
Lip, Oral Cavity and Pharynx
Status: Active/Enrolling
Sponsor: RTOG (1008)
A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Lay Description:
HIPAA
Informed Consent
Protocol
...details...
CTO#: 101639
Other Hematopoietic
Status: Active/Enrolling
Sponsor: Incyte (INCB 18424-261)
An Open Label Assessment of an Alternative Dosing Strategy of Ruxolitinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera-Myelofibrosis and Post-Essential Thrombocythemia-Myelofibrosis
Lay Description:
HIPAA
Informed Consent
Protocol
...details...
CTO#: 101635
Breast-Female
Status: Active/Enrolling
Sponsor: MUSC ()
Feasibility Study of Breast Cancer Candidate Genes in Three Population Groups In South Carolina
Lay Description:
No Documents currently available
...details...
CTO#: 101634
Multiple Myeloma
Status: Active/Enrolling
Sponsor: Onyx (2011-002)
Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients with Relapsed and Refractory Disease
Lay Description:
HIPAA
Informed Consent
Protocol
...details...
CTO#: 101633
Breast-Female
Status: Active/Enrolling
Sponsor: ECOG (E2108)
A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
Lay Description:
HIPAA
Informed Consent
Protocol
...details...
CTO#: 101632
Status: Active/Enrolling
Sponsor: MUSC ()
Impact of nutritional parameters on outcome after pediatric hematopoietic stem cell transplantation
Lay Description:
No Documents currently available
...details...
CTO#: 101629
Breast-Female
Status: Active/Enrolling
Sponsor: RTOG (1005)
A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer.
Lay Description:
HIPAA
Informed Consent
Protocol
...details...
CTO#: 101628
Breast-Female
Status: Active/Enrolling
Sponsor: SWOG (S1007)
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Postive Nodes, Hormone Receptor-Positive and HER2 negative Breast Cancer with Recurrence Score of 25 or less.
Lay Description:
HIPAA
Informed Consent_Step 1
Informed Consent_Step 2
Protocol
...details...
CTO#: 101626
Status: Active/Enrolling
Sponsor: Oncothyreon Inc. (PX-866-003)
Phase 1/2 study of PX-866 and cetuximab
Lay Description:
HIPAA
Informed Consent
Protocol
...details...
CTO#: 101622
Breast-Female
Status: Active/Enrolling
Sponsor: MUSC ()
Paclitaxel Induced Peripheral Neuropathy in Breast Cancer: Exploratory Study of the Role of Deoxysphingolipids
Lay Description:
HIPAA
Informed Consent
Protocol
...details...
CTO#: 101619
Non-Hodgkins Lymphoma
Status: Active/Enrolling
Sponsor: Sanofi-Aventis (TCD12012)
A Phase 1b, multicenter, open-label, dose-escalation study of SAR245409 to evaluate the safety, tolerability, and clinical activity of SAR245409 in combination with bendamustine and/or rituximab in patients with relapsed or refractory indolent B-cell non Hodgkin lymphoma, mantle cell lymphoma, or chronic lymphocytic leukemia.
Lay Description:
Consent
HIPAA
Optional Consent
Optional HIPAA
Pregnant Partner HIPAA
Protocol
...details...
CTO#: 101618
Breast-Female
Status: Active/Enrolling
Sponsor: Genentech, Inc. (GDC4950g)
A PHASE II, DOUBLE-BLIND,PLACEBO-CONTROLLED, RANDOMIZED STUDY
OF GDC-0941 OR GDC-0980 WITH FULVESTRANT VERSUS FULVESTRANT IN
ADVANCED OR METASTATIC BREAST CANCER IN PATIENTS RESISTANT TO AROMATASE INHIBITOR THERAPY
Lay Description:
HIPAA
Main Consent
Optional Consent
Protocol
Spanish HIPAA
Spanish Informed Consent
Spanish Patient Materials
...details...
CTO#: 101615
Lymphoid Leukemia
Status: Active/Enrolling
Sponsor: SWOG (S0805)
Phase II Study of Combination of Hyper-CVAD and Dasatinib with or without allogeneic stem cell transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL).
Lay Description:
HIPAA
Informed Consent
Protocol
...details...
CTO#: 101614
Lymphoid Leukemia
Status: Active/Enrolling
Sponsor: SWOG (0910)
A Phase II Study of Epratuzumab (NSC-716711) in Combination with Cytarabine and Clofarabine for Patients with Relapsed or Refractory Ph-Negative Precursor B-cell Acute Lymphoblastic Leukemia (ALL).
Lay Description:
HIPAA
Informed Consent
Protocol
...details...
CTO#: 101612
Lip, Oral Cavity and Pharynx
Status: Active/Enrolling
Sponsor: MUSC ()
Salivary Morbidity Following Radioactive Iodine Treatment for Thyroid
Carcinoma
Lay Description:
No Documents currently available
...details...
CTO#: 101611
Breast-Female
Status: Active/Enrolling
Sponsor: MUSC ()
Correlating the imaging features of various types of breast cancers with clinical presentation and pathological characteristics of the tumors
Lay Description:
No Documents currently available
...details...
CTO#: 101604
Breast-Female
Status: Active/Enrolling
Sponsor: NCIC CTG (MA.32)
A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Lay Description:
HIPAA
Informed Consent
Protocol
...details...
CTO#: 101596
Lung
Status: Active/Enrolling
Sponsor: MUSC (BIBW 2992)
Molecular Effects of Afatinib: A Window of Opportunity Trial in Early Stage NSCLC
Lay Description:
Drug Diary
HIPAA
Informed Consent
Protocol
...details...
CTO#: 101593
Status: Active/Enrolling
Sponsor: National Marrow Donor Program (10-CBA)
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
Lay Description:
Informed Consent/HIPAA combined
Protocol
...details...
CTO#: 101589
Other Hematopoietic
Status: Active/Enrolling
Sponsor: Onconova Therapeutics, Inc. (04-21)
A Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01919.Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine
Lay Description:
HIPAA
Informed Consent
Protocol
...details...
CTO#: 101587
Lung
Status: Active/Enrolling
Sponsor: Merrimack Pharmaceuticals, Inc. (MM-121-01-1)
A Phase 1-2 Trial of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer
Lay Description:
HIPAA
Informed Consent
Protocol
...details...
CTO#: 101584
Lung
Status: Active/Enrolling
Sponsor: MUSC ()
A Retrospective Study to Assess the Correlation between Thyroid Transcription Factor-1 Expression and driver mutations in Non Small Cell Lung Cancer.
Lay Description:
Protocol
...details...
CTO#: 101583
Status: Active/Enrolling
Sponsor: MUSC ()
Accruing Preliminary Data towards Testing the Hypothesis that Manual Therapy (Therapeutic Massage) Ameliorates Signs, Symptoms and Quality of Life Issues Associated with Chemotherapy-Induced Peripheral Neuropathy
Lay Description:
No Documents currently available
...details...
CTO#: 101582
Status: Active/Enrolling
Sponsor: MUSC ()
Comprehensive assessment of the clinical and pathologic characteristics of perineural invasion in patients with cutaneous squamous cell carcinoma
Lay Description:
No Documents currently available
...details...
|
|
|
|
|
|
 |